These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 37414221)
1. Dissolving microneedles-based programmed delivery system for enhanced chemo-immunotherapy of melanoma. Tian Y; Jing H; Wang Q; Hu S; Wu Z; Duan Y J Control Release; 2023 Aug; 360():630-646. PubMed ID: 37414221 [TBL] [Abstract][Full Text] [Related]
2. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551 [TBL] [Abstract][Full Text] [Related]
3. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway. Liu D; Li K; Gong L; Fu L; Yang D Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659 [TBL] [Abstract][Full Text] [Related]
4. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer. Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867 [TBL] [Abstract][Full Text] [Related]
5. Combinational Chemoimmunotherapy for Breast Cancer by Codelivery of Doxorubicin and PD-L1 siRNA Using a PAMAM-Incorporated Liposomal Nanoplatform. Hu Q; Yao J; Wang X; Wang Y; Fu X; Ma J; Lin H; Xu J; Shen L; Yu X ACS Appl Mater Interfaces; 2022 Feb; 14(7):8782-8792. PubMed ID: 35138103 [TBL] [Abstract][Full Text] [Related]
6. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases. Mu X; Zhang M; Wei A; Yin F; Wang Y; Hu K; Jiang J Nanoscale; 2021 May; 13(19):8998-9008. PubMed ID: 33973580 [TBL] [Abstract][Full Text] [Related]
7. Upregulation of MHC-I and downregulation of PD-L1 expression by doxorubicin and deferasirox codelivered liposomal nanoparticles for chemoimmunotherapy of melanoma. Song P; Han X; Zheng R; Yan J; Wu X; Wang Y; Zhang H Int J Pharm; 2022 Aug; 624():122002. PubMed ID: 35817272 [TBL] [Abstract][Full Text] [Related]
8. Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy. Qiu N; Liu Y; Liu Q; Chen Y; Shen L; Hu M; Zhou X; Shen Y; Gao J; Huang L Biomaterials; 2021 Feb; 269():120604. PubMed ID: 33383300 [TBL] [Abstract][Full Text] [Related]
9. Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma. Chen Y; Luo X; Liu Y; Zou Y; Yang S; Liu C; Zhao Y Int J Nanomedicine; 2022; 17():3989-4008. PubMed ID: 36105615 [TBL] [Abstract][Full Text] [Related]
10. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma. Wang C; Shi X; Song H; Zhang C; Wang X; Huang P; Dong A; Zhang Y; Kong D; Wang W Biomaterials; 2021 Jan; 268():120579. PubMed ID: 33278683 [TBL] [Abstract][Full Text] [Related]
11. Design of an Injectable Polypeptide Hydrogel Depot Containing the Immune Checkpoint Blocker Anti-PD-L1 and Doxorubicin to Enhance Antitumor Combination Therapy. Shi Y; Li D; He C; Chen X Macromol Biosci; 2021 Jun; 21(6):e2100049. PubMed ID: 33871152 [TBL] [Abstract][Full Text] [Related]
12. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959 [TBL] [Abstract][Full Text] [Related]
13. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy. He ZD; Zhang M; Wang YH; He Y; Wang HR; Chen BF; Tu B; Zhu SQ; Huang YZ Acta Pharmacol Sin; 2021 Sep; 42(9):1516-1523. PubMed ID: 33311600 [TBL] [Abstract][Full Text] [Related]
14. Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapy. Xie F; Tang S; Zhang Y; Zhao Y; Lin Y; Yao Y; Wang M; Gu Z; Wan J ACS Nano; 2024 Jan; 18(2):1690-1701. PubMed ID: 38165832 [TBL] [Abstract][Full Text] [Related]
15. A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle. Feng ZH; Li ZT; Zhang S; Wang JR; Li ZY; Xu MQ; Li H; Zhang SQ; Wang GX; Liao A; Zhang X Acta Biomater; 2021 Dec; 136():495-507. PubMed ID: 34619371 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of post-surgery tumour recurrence via a sprayable chemo-immunotherapy gel releasing PD-L1 antibody and platelet-derived small EVs. Zhao J; Ye H; Lu Q; Wang K; Chen X; Song J; Wang H; Lu Y; Cheng M; He Z; Zhai Y; Zhang H; Sun J J Nanobiotechnology; 2022 Feb; 20(1):62. PubMed ID: 35109878 [TBL] [Abstract][Full Text] [Related]
17. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro. Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307 [TBL] [Abstract][Full Text] [Related]
18. CD4 Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929 [TBL] [Abstract][Full Text] [Related]
19. Dissolving Microneedles with Spatiotemporally controlled pulsatile release Nanosystem for Synergistic Chemo-photothermal Therapy of Melanoma. Qin W; Quan G; Sun Y; Chen M; Yang P; Feng D; Wen T; Hu X; Pan X; Wu C Theranostics; 2020; 10(18):8179-8196. PubMed ID: 32724465 [TBL] [Abstract][Full Text] [Related]
20. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics. Han X; Li H; Zhou D; Chen Z; Gu Z Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]